PCN124 COST-UTILITY ANALYSIS OF DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) ON CHRONIC (CP), ACCELERATED (AP) AND BLAST (BP) PHASES IN BRAZIL
Abstract
Authors
E Asano M Nita A Moellmann-Coelho R Rached B Donato E Rahal